AP3286A - Glucagon analogues - Google Patents

Glucagon analogues

Info

Publication number
AP3286A
AP3286A AP2013006669A AP2013006669A AP3286A AP 3286 A AP3286 A AP 3286A AP 2013006669 A AP2013006669 A AP 2013006669A AP 2013006669 A AP2013006669 A AP 2013006669A AP 3286 A AP3286 A AP 3286A
Authority
AP
ARIPO
Prior art keywords
glucagon analogues
glucagon
analogues
Prior art date
Application number
AP2013006669A
Other languages
English (en)
Other versions
AP2013006669A0 (en
Inventor
Eddi Meier
Ditte Riber
Jens Rosengren Daugaard
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3286(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of AP2013006669A0 publication Critical patent/AP2013006669A0/xx
Application granted granted Critical
Publication of AP3286A publication Critical patent/AP3286A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2013006669A 2010-06-23 2011-06-23 Glucagon analogues AP3286A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201000550 2010-06-23
US35862310P 2010-06-25 2010-06-25
PCT/DK2011/000067 WO2011160630A2 (en) 2010-06-23 2011-06-23 Glucagon analogues

Publications (2)

Publication Number Publication Date
AP2013006669A0 AP2013006669A0 (en) 2013-01-31
AP3286A true AP3286A (en) 2015-05-31

Family

ID=44630045

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006669A AP3286A (en) 2010-06-23 2011-06-23 Glucagon analogues

Country Status (23)

Country Link
US (2) US9403894B2 (xx)
EP (1) EP2585481B1 (xx)
JP (1) JP5937582B2 (xx)
KR (1) KR20130086339A (xx)
CN (1) CN103038250A (xx)
AP (1) AP3286A (xx)
AR (1) AR081975A1 (xx)
AU (1) AU2011269427A1 (xx)
BR (1) BR112012033227A2 (xx)
CA (1) CA2802889A1 (xx)
CL (1) CL2012003643A1 (xx)
CO (1) CO6660484A2 (xx)
EA (1) EA201291233A1 (xx)
EC (1) ECSP12012351A (xx)
MX (1) MX2012014774A (xx)
NZ (1) NZ604033A (xx)
PE (1) PE20130326A1 (xx)
PH (1) PH12012502461A1 (xx)
SG (1) SG186276A1 (xx)
TN (1) TN2012000567A1 (xx)
TW (1) TW201202265A (xx)
UY (1) UY33462A (xx)
WO (1) WO2011160630A2 (xx)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013431A (es) 2005-05-04 2008-01-18 Zealand Pharma As Analogos del peptido 2 semejante al glucagon.
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
PL2370462T3 (pl) 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
EA020537B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
KR20130086343A (ko) 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
SG192038A1 (en) * 2011-01-20 2013-08-30 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
KR20140114845A (ko) * 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
TR201802689T4 (tr) * 2012-05-03 2018-03-21 Zealand Pharma As Glukagon benzeri peptit-2 (glp-2) analogları.
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
SG11201407860PA (en) 2012-06-14 2014-12-30 Sanofi Sa Exendin-4 peptide analogues
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
US9546205B2 (en) 2012-09-17 2017-01-17 Imperial Innovations Limited Peptide analogues of glucagon and GLP1
GB2505941A (en) * 2012-09-17 2014-03-19 Imp Innovations Ltd Peptide analogues of glucagon for the treatment of obesity and diabetes
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重glp1/gipまたは三方glp1/gip/グルカゴンアゴニストとしてのエキセンジン−4誘導体
CN105102427B (zh) 2013-03-21 2018-09-07 赛诺菲-安万特德国有限公司 含有环状酰亚胺的肽产物的合成
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
AR095986A1 (es) 2013-04-03 2015-11-25 Sanofi Sa Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
LT3057984T (lt) 2013-10-17 2018-12-27 Zealand Pharma A/S Acilinti gliukagono analogai
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-glp-1-gip 삼원 효능제 화합물
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/gip受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽-4(exendin-4)胜肽類似物
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
TN2017000349A1 (en) 2015-02-17 2019-01-16 Lilly Co Eli Nasal powder formulation for treatment of hypoglycemia
EA035791B1 (ru) 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
EP3888667B1 (en) 2016-06-09 2023-10-25 AmideBio LLC Glucagon analog and methods of use thereof
RS61937B1 (sr) 2016-08-05 2021-07-30 Boehringer Ingelheim Int Oksadiazolopiridin derivati za primenu kao inhibitori grelin o-acil transferaze (goat)
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
KR101887577B1 (ko) * 2016-10-19 2018-09-10 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物
SG10201911851VA (en) 2016-12-09 2020-02-27 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
ES2894629T3 (es) 2017-06-16 2022-02-15 Zealand Pharma As Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
SMT202400097T1 (it) * 2017-08-16 2024-05-14 Dong A St Co Ltd Analogo peptidico acilato dell'ossitomodulina
JOP20200187A1 (ar) 2018-02-02 2020-07-29 Boehringer Ingelheim Int مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat)
CN111630055B (zh) 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
MX2020008116A (es) 2018-02-02 2020-09-25 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).
CN111655700B (zh) 2018-02-02 2023-07-18 勃林格殷格翰国际有限公司 作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物
CN112543763B (zh) * 2018-04-10 2024-11-05 赛诺菲-安万特德国有限公司 从固相裂解固相结合肽的方法
ES2928207T5 (en) 2018-04-10 2026-02-16 Sanofi Aventis Deutschland Lixisenatide synthesis with capping
CA3123979A1 (en) 2018-12-21 2020-06-25 Jiangsu Hengrui Medicine Co., Ltd. Bispecific protein
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
CN115380043A (zh) * 2019-08-13 2022-11-22 安医健有限公司 艾塞那肽类似物及其用途
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
EP4153599B1 (en) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
PL4153600T3 (pl) 2020-05-22 2024-12-16 Boehringer Ingelheim International Gmbh Sposób ciągły wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4- b]pirydynokarboksylanu alkilu
CN113278060B (zh) * 2020-05-29 2022-03-25 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
MX2024005969A (es) 2022-05-30 2024-06-11 Zealand Pharma As Formulaciones liquidas de analogos de amilina.
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
WO2010070255A1 (en) * 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2011088837A1 (en) * 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Glp―1誘導体
EP0932614A1 (en) 1996-09-09 1999-08-04 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ,インコーポレイテッド 新規なエキセンジンアゴニスト化合物
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
HUP0200297A3 (en) 1999-03-17 2002-09-30 Novo Nordisk As Method for acylating peptides and the glutaminic acid derivatives as acylating agents
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US20060217290A1 (en) 2003-04-29 2006-09-28 Kohn Wayne D Insulin analogs having protracted time action
CA2612063A1 (en) 2005-06-13 2006-12-21 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
US20090202497A1 (en) 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
EP2471810A1 (en) 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Oxyntomodulin derivatives
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2025684A1 (en) 2007-08-15 2009-02-18 Zealand Pharma A/S Glucagon analogues
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
BRPI0907119A2 (pt) 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
WO2009132129A2 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
TWI541023B (zh) 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
ES2552636T3 (es) 2008-07-31 2015-12-01 Case Western Reserve University Insulina estabilizada por halógenos
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
EA020537B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation インスリン類似体
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
KR20130086343A (ko) 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
SG192038A1 (en) 2011-01-20 2013-08-30 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
KR20140114845A (ko) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
LT3057984T (lt) 2013-10-17 2018-12-27 Zealand Pharma A/S Acilinti gliukagono analogai
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
WO2010070255A1 (en) * 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2011088837A1 (en) * 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions

Also Published As

Publication number Publication date
US9403894B2 (en) 2016-08-02
JP5937582B2 (ja) 2016-06-22
UY33462A (es) 2012-01-31
SG186276A1 (en) 2013-01-30
AU2011269427A1 (en) 2012-12-20
US20130157935A1 (en) 2013-06-20
CO6660484A2 (es) 2013-04-30
PE20130326A1 (es) 2013-03-17
WO2011160630A3 (en) 2012-02-16
US20160304576A1 (en) 2016-10-20
CL2012003643A1 (es) 2013-08-02
EA201291233A1 (ru) 2013-07-30
AP2013006669A0 (en) 2013-01-31
NZ604033A (en) 2014-12-24
WO2011160630A2 (en) 2011-12-29
TW201202265A (en) 2012-01-16
ECSP12012351A (es) 2013-01-31
MX2012014774A (es) 2013-01-29
JP2013534919A (ja) 2013-09-09
KR20130086339A (ko) 2013-08-01
CA2802889A1 (en) 2011-12-29
EP2585481B1 (en) 2015-08-19
BR112012033227A2 (pt) 2017-06-20
PH12012502461A1 (en) 2013-02-18
AR081975A1 (es) 2012-10-31
EP2585481A2 (en) 2013-05-01
TN2012000567A1 (en) 2014-04-01
CN103038250A (zh) 2013-04-10

Similar Documents

Publication Publication Date Title
AP2013006669A0 (en) Glucagon analogues
AP2013006671A0 (en) Glucagon analogues
ZA201206838B (en) Novel glucagon analogues
IL232800A0 (en) Glucagon analog
ZA201702364B (en) Glucagon analogues
IL231199A0 (en) New analogs of glucagon
IL237518A0 (en) Glucagon analog
ZA201306514B (en) Novel glucagon analogues
ZA201104592B (en) Glucagon analogues
IL213478A0 (en) Glucagon analogues
IL213477A0 (en) Glucagon analogues
ZA201104591B (en) Glucagon analogues
SG10201606027VA (en) Scaffolding
EP2576612A4 (en) INSULIN ANALOG
GB2479441B (en) Coelenterazine analogues
GB201018245D0 (en) Platform slot recovery
HUP1100726A2 (en) Component
GB201004491D0 (en) Quinazoline analogues
GB201116856D0 (en) Schraubspindellagerung
HK1177622A (en) Glucagon analogues
HK1177621A (en) Glucagon analogues
GB201018136D0 (en) Project
AU337827S (en) Ladder
ZA201109183B (en) Prop